Nintedanib slows FVC decline in autoimmune-related interstitial lung disease


Nintedanib slows the rate of forced vital capacity decline in patients with fibrosing autoimmune disease-related interstitial lung disease, with adverse events manageable for most, according to data published in Arthritis & Rheumatology.

“A substantial proportion of patients with systemic autoimmune disease, such as rheumatoid arthritis, dermatomyositis and polymyositis, scleroderma, Sjogren’s syndrome and others, develop various forms of lung involvement that have profound effects on their quality of life and life expectancy,” Eric L. Matteson, MD, of the Mayo Clinic College of Medicine and Science, in Rochester, Minnesota, told Healio. “There is a direct correlation between quality of life and survivorship, and the extent of fibrosis on imaging and loss of pulmonary function.

RH0222Matteson_Graphic_01
Nintedanib slows the rate of forced vital capacity decline in patients with fibrosing autoimmune disease-related ILD, with adverse events manageable for most, according to data.

“Recently, antifibrotic therapies have become available for the management of progressive lung fibrosis,” he added. “However, it has not been clear if antifibrotic therapy might also lessen the rate of decline in lung function among patients with progressive autoimmune disease-related interstitial lung disease, for whom good treatment options have not been available.”

To examine the efficacy and safety of nintedanib (Ofev, Boehringer Ingelheim) in patients with progressive fibrosing ILDs related to autoimmune disease, Matteson and colleagues analyzed data from the INBUILD trial. According to the researchers INBUILD was a randomized, double-blind, placebo-controlled study conducted across 15 countries in 663 patients with ILDs other than idiopathic pulmonary fibrosis. Additional eligibility criteria included diffuse fibrosing lung disease of greater than 10% on HRCT, predicted FVC of 45% or greater and diffusing capacity for carbon monoxide from 30% to less than 80% predicted.

Matteson_Eric_2022

Eric L. Matteson

Participants were also required to exhibit ILD progression within 24 months prior to screening despite treatment. Patients receiving azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus (Prograf, Astellas Pharma), rituximab (Rituxan, Genentech), cyclophosphamide or more than 20 mg of oral glucocorticoids per day were excluded.

Participants were randomly assigned to receive either 150 mg of nintedanib twice daily or a placebo. After 52 weeks of treatment, participants entered a variable period in which they continued to receive blinded treatment until all had completed the trial.

For this analysis, Matteson and colleagues presented data from the 170 participants with ILD related to autoimmune disease.

According to the researchers, the rate of FVC decline over 52 weeks was –75.9 mL per year in the nintedanib group, compared with –178.6 mL per year among those who received a placebo (difference = 102.7; 95% CI, 23.2-182.2). Additionally, the researchers found no heterogeneity in the effect of nintedanib, compared with placebo, across subgroups by ILD diagnosis (P = .91).

The most frequent adverse event was diarrhea, reported in 63.4% of those treated with nintedanib and in 27.3% of the placebo group. Adverse events led to permanent treatment discontinuation in 17.1% and 10.2% of participants in the nintedanib and placebo groups, respectively.

“We found that nintedanib significantly reduced the rate of decline in forced vial capacity by 58%, and that the effects were very similar to what was seen in subjects who had pulmonary fibrosis not related to an underlying autoimmune disease,” Matteson said. “The frequency of the known side effect of diarrhea was similar in subjects with and without underlying autoimmune disease. The results demonstrate that nintedanib significantly slows the rate of decline in pulmonary function in autoimmune disease-related ILD, a finding that can aid in the management of this complex disease manifestation.”

‘We must do better’: Celebrity cases pull autoimmunity epidemic into limelight


Every so often, autoimmunity hits the mainstream media. Usually this happens when a celebrity bravely uses their place in the limelight to raise awareness by publicly sharing news about their diagnosis.

Thanks to celebrities like Christina Applegate, Caroline Wozniacki, Selena Gomez and many others over the years, we are all a little wiser about the personal toll of living with autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and lupus.

Scleroderma1_89402605
“Available autoimmune treatments fail three out of four people,” Nicole Bundy, MD, said. “We must do better. This involves a massive shift in mindset to acknowledge the central role that diet, lifestyle and environment play in the onset and course of autoimmune disease.” Source: Adobe Stock.

Last month, Bob Saget’s death became the reason why the topic of autoimmunity has come up again. His story involved the tragic loss of his sister, Gay Saget, at age 47 from scleroderma, the hallmark of which is tightening, or fibrosis, of the skin. The vascular abnormalities that lead to these skin changes can also damage internal organs, especially the esophagus, intestines, lungs, heart and kidneys.

An active champion of fundraising and research, Saget sat on the board of the Scleroderma Research Foundation, helping to raise more than $26 million for research. In one of his last interviews prior to his death, he spoke emotionally about raising awareness to honor his late sister’s memory: “I can’t watch what happened to my sister happen to more people.”

Bundy_Nicole_2022

Nicole Bundy

Scleroderma, also known as systemic sclerosis, is a rare disease, believed to affect approximately 30 out of one million people annually. Other autoimmune conditions like MS, RA and lupus, among many others, are not so rare.

Today more than 30 million Americans, or one out of five, live with an autoimmune condition, a vast cry from the significantly lower ratio of 1 in 400 affected a mere two generations ago. These numbers don’t include the surge in patients suffering from persistent COVID-19-related symptoms, estimated at 10% to 30% of all those infected with the virus and believed, at least in some of those cases, to be caused by an autoimmune reaction. With research showing a growing prevalence of ANAs — the main biomarker indicative of autoimmunity — triggers of autoimmune disease, like viruses, toxins and diet, will only continue to put more people at risk.

Autoimmunity is the epidemic no one is talking about, or at least not talking about enough. More than 80 conditions and disorders fall under the autoimmune umbrella and while every diagnosis may be different, on a biological level they are quite similar: The body turns on itself, causing the immune system to attack otherwise healthy organs, tissues or cells. Rarely, however, does this come with the kind of death sentence suffered in the case of Gay Saget, who died 3 short years after her scleroderma diagnosis.

Instead, what follows for most is a lifetime of managing mysterious “invisible” symptoms that can be severely debilitating, from fatigue, headaches and brain fog to pain, anxiety and skin and digestive problems. Unpredictable flares that come and go can reduce productivity, affect emotional wellbeing, and alienate people from their family and friends.

Available autoimmune treatments fail three out of four people. New research underway in the UK is trying to change that by looking at DNA to uncover disease pathways for better matching patients to therapies, as well as guiding research for effective, new treatments. In the meantime, drugs like prednisone and cortisone provide temporary relief from some of the symptoms yet do nothing to improve quality of life in the long term.

We must do better. This involves a massive shift in mindset to acknowledge the central role that diet, lifestyle and environment play in the onset and course of autoimmune disease. Published research has established that only 20% of our immune system is controlled by our genetics. The rest can be any combination of factors in a “haystack” of variables like food, nutrition, lifestyle, toxins, UV light, stress, sleep, pathogens and others.

In the absence of a cure, and with even the best of current treatments far from optimal, turning our attention to how lifestyle changes can help co-manage autoimmunity is imperative. Real world evidence can guide personalized interventions to help replace our current “trial and error” approach to drug treatment and lifestyle adjunctive care and even — if the signs and symptoms of autoimmunity are caught early enough — drive prevention.

Accepting that the multitude of external factors in our lives can in fact trigger or influence the course of autoimmunity is one big step we can take toward helping patients understand what is within their grasp to control. Our understanding of conditions like scleroderma has come a long way since Gay Saget was diagnosed in the 1980s, thanks to growing medical knowledge, continuous research and passionate advocates like Bob Saget. Our ability to diagnose and treat individual cases of autoimmunity, including those that are rare or undefined, will hopefully only keep getting better.

In the meantime, tackling the growing epidemic of autoimmunity must also include helping those affected learn what steps they can take to improve their quality of life. This goes for those living with autoimmunity with or without a confirmed diagnosis, which can take up to 5 to 7 years after symptom onset, depending on the condition.

Evolving research about the human immune system continues to help us better understand how interventions based on personal lifestyle triggers can support treatment today. We have seen this awareness about lifestyle become standard of care for heart disease and diabetes. It is time this approach is embraced for autoimmune disease.

Study shows stem cell transplant is better than drug therapy for scleroderma


https://speciality.medicaldialogues.in/study-shows-stem-cell-transplant-is-better-than-drug-therapy-for-scleroderma/